| 1 |
王克安. 中国糖尿病的防治和研究 [J]. 中华流行病学杂志,1999, 20(5): 6-9.
|
| 2 |
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362(12): 1090-1101.
|
| 3 |
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes:estimates for the year 2000 and projections for 2030 [J]. Diabetes care, 2004, 27(5): 1047-1053.
|
| 4 |
Standards of medical care for patients with diabetes mellitus [J].Diabetes care, 2003, 26 Suppl 1: 33-50.
|
| 5 |
Ritz E, Zeng XX, Rychlik I. Clinical manifestation and natural history of diabetic nephropathy [J]. Contrib Nephrol, 2011, 170:19-27.
|
| 6 |
金波, 刘志红, 葛永纯, 等. 肾活检患者中糖尿病肾病流行病学特点的变迁 [J]. 肾脏病与透析肾移植杂志, 2009, 18(02):133-139.
|
| 7 |
Gambaro G, Cavazzana AO, Luzi P, et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats [J]. Kidney Int, 1992, 42(2): 285-291.
|
| 8 |
Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di. N. A. S. randomized trial [J].J Am Soc Nephrol, 2002, 13(6): 1615-1625.
|
| 9 |
Lewis EJ, Lewis JB, Greene T, et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial [J]. Am J Kidney Dis, 2011, 58(5):729-736.
|
| 10 |
Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy[J]. J Am Soc Nephrol, 2012, 23(1): 123-130.
|
| 11 |
RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease [J]. J Am Soc Nephrol,2009, 20(8): 1765-1775.
|
| 12 |
Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy [J]. J Am Soc Nephrol, 2011, 22(6): 1144-1151.
|
| 13 |
Aggarwal HK, Jain D, Talapatra P, et al. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy [J]. Ren fail, 2010,32(8): 941-946.
|
| 14 |
Burney BO, Kalaitzidis RG, Bakris GL. Novel therapies of diabetic nephropathy [J]. Curr Opin Nephrol Hypertens, 2009,18(2): 107-111.
|
| 15 |
Persson F, Rossing P, Schjoedt KJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes [J]. Kidney Int, 2008, 73(12): 1419-1425.
|
| 16 |
Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy [J]. N Engl J Med,2008, 358(23): 2433-2446.
|
| 17 |
Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE):rationale and study design [J]. Nephrol Dial Transplant, 2009,24(5): 1663-1671.
|
| 18 |
Parving HH, Brenner BM, McMurray JJ, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) [J]. J Renin Angiotensin Aldosterone Syst, 2012,13(3): 387-393.
|
| 19 |
Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded;product information updated. http://www.reuters.com/article/2012/04/19/idUS234551+19-Apr-2012+HUG20120419.Accessed Apr 2012.
|
| 20 |
Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes [J]. Endocr rev, 2002, 23(5): 599-622.
|
| 21 |
Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes [J]. N Engl J Med,2011, 365(4): 327-336.
|
| 22 |
De Zeeuw D, Akizawa T, Agarwal R, et al. Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) [J]. Am J Nephrol, 2013, 37(3): 212-222.
|
| 23 |
Endo K, Miyashita Y, Sasaki H, et al. Probucol delays progression of diabetic nephropathy [J]. Diabetes Res Clin Pract, 2006, 71(2):156-163.
|
| 24 |
Chen YM, Ng YY, Lin SL, et al. Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats [J]. Nephrol Dial Transplant,2004, 19(5): 1106-1115.
|
| 25 |
Lin SL, Chen YM, Chien CT, et al. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney [J]. J Am Soc Nephrol, 2002, 13(12): 2916-2929.
|
| 26 |
Roozbeh J, Banihashemi MA, Ghezlou M, et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy [J]. Renal fail, 2010, 32(2):172-178.
|
| 27 |
Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, et al.Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results [J]. J Diabetes Complications, 2011, 25(5): 314-319.
|
| 28 |
Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients study. Clinical Trial NCT01382302. www. clinicaltrials.gov. Accessed December, 2011.
|
| 29 |
Diaz VA, Mainous AG, Carek PJ, et al. The association of vitamin D deficiency and insufficiency with diabetic nephropathy:implications for health disparities [J]. J Am Board Fam Med,2009, 22(5): 521-527.
|
| 30 |
Porsti IH. Expanding targets of vitamin D receptor activation:downregulation of several RAS components in the kidney [J].Kidney Int, 2008, 74(11): 1371-1373.
|
| 31 |
Rojas-Rivera J, De La Piedra C, Ramos A, et al. The expanding spectrum of biological actions of vitamin D [J]. Nephrol Dial Transplant, 2010, 25(9): 2850-2865.
|
| 32 |
De Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial [J]. Lancet, 2010, 376(9752): 1543-1551.
|
| 33 |
Kim MJ, Frankel AH, Donaldson M, et al. Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensinaldosterone system inhibition [J]. Kidney Int, 2011, 80(8): 851-860.
|
| 34 |
Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis [J]. Am J Kidney Dis, 2010, 55(5): 835-847.
|
| 35 |
Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes [J]. J Clin Endocrinol Metab, 2010, 95(10): 4560-4565.
|
| 36 |
Nissen SE, Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality [J]. Arch Intern Med, 2010, 170(14): 1191-1201.
|
| 37 |
Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone [J]. Fundam Clin Pharmacol, 2009, 23(6): 675-679.
|
| 38 |
Komers R, Oyama TT, Beard DR, et al. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure [J]. Kidney Int, 2011, 79(4): 432-442.
|
| 39 |
Kolavennu V, Zeng L, Peng H, et al. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control [J]. Diabetes, 2008, 57(3): 714-723.
|
| 40 |
Komers R . Rho kinase inhibition in diabetic nephropathy [J].Curr Opin Nephrol Hypertens, 2011, 20(1): 77-83.
|
| 41 |
Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology [J]. Circ Res, 2006, 98(3): 322-334.
|
| 42 |
张慧, 朱孝春, 王莉, 等. 法舒地尔治疗2型糖尿病伴白蛋白尿的临床观察 [J]. 东南国防医药, 2011(01): 66-67.
|
| 43 |
Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy [J]. Am J Pathol, 2003,162(4): 1123-1137.
|
| 44 |
Reiniger N, Lau K, McCalla D, et al. Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse [J].Diabetes, 2010, 59(8): 2043-2054.
|
| 45 |
Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy [J]. Am J Nephrol, 2004, 24(1): 32-40.
|
| 46 |
Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy [J]. Am J Nephrol,2007, 27(6): 605-614.
|
| 47 |
Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy [J]. J Am Soc Nephrol, 2012, 23(1): 131-136.
|
| 48 |
House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial [J]. JAMA, 2010, 303(16): 1603-1609.
|
| 49 |
Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease [J]. Eur J Clin Invest, 2006,36( Suppl) 3: 78-88.
|
| 50 |
Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy [J]. J Am Soc Nephrol, 2010, 21(3): 527-535.
|
| 51 |
Brownlee M. Biochemistry and molecular cell biology of diabetic complications [J]. Nature, 2001, 414(6865): 813-820.
|
| 52 |
Meier M, Park JK, Overheu D, et al. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model[J]. Diabetes, 2007, 56(2): 346-354.
|
| 53 |
Gilbert RE, Kim SA, Tuttle KR, et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes [J]. Diabetes care, 2007, 30(4):995-996.
|
| 54 |
Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes [J]. Diabetes care, 2005,28(11): 2686-2690.
|
| 55 |
Ghorbani A, Omidvar B, Beladi-Mousavi SS, et al. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial [J]. Nefrologia, 2012, 32(6):790-796.
|